Targeted News Service

AstraZeneca: Lynparza Plus Abiraterone Approved in the US for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
June 02, 2023

WILMINGTON, Delaware, June 2 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:

AstraZeneca and Merck & Co., Inc's, known as MSD outside the US and Canada, LYNPARZA(R) (olaparib) in combination with abiraterone and prednisone or prednisolone has been approved in the US for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).

This a . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your Affiliation	Government Newspaper / Media Business Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions or comments:

Click here for more information about our products

Existing Customer Login

Targeted News Service Document Request Form